Executive Interviews

  1. Embracing Challenges And Executing A Successful IPO 5/2/2022

    John Jacobs, CEO of Harmony Biosciences, discusses the challenges and lessons learned from when his company transitioned from private to public.

  2. Platforms To Pipelines: Part 2 5/2/2022

    In part 2 of this series, we cover each company’s future plans, as well as their leaders’ observations of the platform-to-pipeline space they are effectively expanding, by joining a gathering crowd of companies now entering it.

  3. Are Cannabinoids The Next Blockbuster Drugs? A Q&A With Jazz Pharma's CEO Bruce Cozadd 5/2/2022

    A Q&A with Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals, on the $7.2 billion acquisition, integration, and future of cannabis drug pioneer GW Pharmaceuticals.

  4. Where Patients Meet Policy: The EveryLife Foundation For Rare Diseases 4/1/2022

    The year before he founded Ultragenyx, Emil Kakkis created the EveryLife Foundation for Rare Diseases, a nonprofit patient advocacy organization focused on the “equitable development of and access to lifesaving diagnoses, treatments, and cures.” We caught up with Annie Kennedy, chief of policy and advocacy at the EveryLife Foundation, to learn more about the issues and policies the foundation is prioritizing this year.

  5. Thinking Differently About Rare Disease Therapies 4/1/2022

    As Ultragenyx continues building its new gene therapy manufacturing facility, CEO and president Dr. Emil Kakkis talks about his unique outlook on the rare disease space.

  6. Beyond Profits To Biopharma Innovation 4/1/2022

    What if, for certain ambitious but traditionally underfunded areas needing innovation, a startup could achieve its ends without the usual for-profit incentives?

  7. What's It Like Being A Termeer Fellow? 4/1/2022

    We reached out to four previous Termeer Network Fellows to find out how the program helped them and what they learned. Participants included Sun Altbach, founder and former CEO and president of PIC Therapeutics; Ana Maiques, CEO, Neuroelectrics; Stan Wang, founder & CEO, Thymmune Therapeutuics; and Natalie Yivgi-Ohana, CEO, Minovia Therapeutics.

  8. Can Caribou Biosciences Top 2021? 3/1/2022

    In 2021, much of Rachel Haurwitz’ hard-earned on-the-job training over the past decade culminated in a series of significant milestones that will undoubtably help position Caribou Biosciences for future growth and success.

  9. Outsourcing From A To ZZ Biotech 3/1/2022

    Kent Pryor, CEO of ZZ Biotech, explains how he’s approached his single-handed “CEO As Outsourcer” role and provides advice to professionals of all positions in any biopharma organization.

  10. Art Of The Startup — Making New Waves 3/1/2022

    As Shoreline’s chairman, CEO, and cofounder, Dr. Kleanthis Xanthopoulos draws on his experience of several decades, starting and running companies that aim to overturn prevailing practices in areas of medicine where practice makes imperfect, with treatments that disappoint patients or prove expensive and impractical for many.